The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
A year of Tigit (and Alzheimer’s) for Roche
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Astra presses on with bispecifics
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
